healthcare technology

Since the start of the pandemic, new technologies have been developed to help reduce the spread of the infection.

Some of the most common safety measures today include measuring a person’s temperature, covering your nose and mouth with a mask, contact tracing, disinfection, and social distancing. Many businesses have adopted various technologies, including those with artificial intelligence (AI) underneath, helping to adhere to the COVID-19 safety measures.

 

As an example, numerous airlines, hotels, subways, shopping malls, and other institutions are already using thermal cameras to measure an individual’s temperature before people are allowed entry. In its turn, public transport in France relies on AI-based surveillance cameras to monitor whether or not people are social-distancing or wearing masks. Another example is requiring the download of contact-tracing apps delivered by governments across the globe.

 

However, there are a number of issues.

 

While many of these solutions help to ensure that COVID-19 prevention practices are observed, many of them have flaws or limits. In this article, we will cover some of the issues creating obstacles for fighting the pandemic.

 

Issue #1. Manual temperature scanning is tricky

Issue #2. Monitoring crowds is even more complex

Issue #3. Contact tracing leads to privacy concerns

Issue #4. UV rays harm eyes and skin

Issue #5. UVC robots are extremely expensive

Issue #6. No integration, no compliance, no transparency

Regardless of the safety measures in place and existing issues, innovations are already playing a vital role in the fight against COVID-19. By improving on existing technology, we can make everyone safer as we all adjust to the new normal.

 

read the details at https://www.altoros.com/blog/whats-wrong-with-ai-tools-and-devices-preventing-covid-19/

 

Imagine you’re a scientist who needs to discover a new antibiotic to fight off a scary disease. How would you go about finding it?

 

Typically, you’d have to test lots and lots of different molecules in the lab until you find one that has the necessary bacteria-killing properties. You might find some contenders that are good at killing the bacteria only to realize that you can’t use them because they also prove toxic to humans. It’s a very long, very expensive, and probably very aggravating process.

 

But what if, instead, you could just type into your computer the properties you’re looking for and have your computer design the perfect molecule for you?

 

That’s the general approach IBM researchers are taking, using an AI system that can automatically generate the design of molecules for new antibiotics.

 

In a new paper, published in Nature Biomedical Engineering, the researchers detail how they’ve already used it to quickly design two new antimicrobial peptides — small molecules that can kill bacteria — that are effective against a bunch of different pathogens in mice.

 

Normally, this molecule discovery process would take scientists years. The AI system did it in a matter of days.

 

That’s great news, because we urgently need faster ways to create new antibiotics.

How IBM’s AI system works

IBM’s new AI system relies on something called a generative model. To understand it at its simplest level, we can break it down into three basic steps.

 

First, the researchers start with a massive database of known peptide molecules.

 

Then the AI pulls information from the database and analyzes the patterns to figure out the relationship between molecules and their properties. It might find that when a molecule has a certain structure or composition, it tends to perform a certain function.

 

This allows it to “learn” the basic rules of molecule design.

 

Finally, researchers can tell the AI exactly what properties they want a new molecule to have. They can also input constraints (for example: low toxicity, please!). Using this info on desirable and undesirable traits, the AI then designs new molecules that satisfy the parameters. The researchers can pick the best one from among them and start testing on mice in a lab.

 

The IBM researchers claim that their approach outperformed other leading methods for designing new antimicrobial peptides by 10 percent. They found that they were able to design two new antimicrobial peptides that are highly potent against diverse pathogens, including multidrug-resistant K. pneumoniae, a bacterium known for causing infections in hospital patients. Happily, the peptides had low toxicity when tested in mice, an important signal about their safety (though not everything that’s true for mice ends up being generalizable to humans).

 

read the original unedited article at  https://www.vox.com/future-perfect/22360573/ai-ibm-design-new-antibiotics-covid-19-treatments

 

read the paper by the IBM researchers - Accelerated antimicrobial discovery via deep generative models and molecular dynamics simulations